NTRK3 gene fusion in an adult ganglioglioma: illustrative case.
EML4-NTRK3
NTRK
ganglioglioma
gene fusion
neurotrophin tyrosine receptor kinase
Journal
Journal of neurosurgery. Case lessons
ISSN: 2694-1902
Titre abrégé: J Neurosurg Case Lessons
Pays: United States
ID NLM: 9918227275606676
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
11
11
2021
accepted:
13
12
2021
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
22
9
2022
Statut:
epublish
Résumé
Gangliogliomas are well-differentiated, slow-growing glioneuronal neoplasms frequently reported to harbor upregulating alterations in the mitogen-activated protein kinase pathway, particularly serine-threonine protein kinase B-RAF alterations. Fusions involving neurotrophin tyrosine receptor kinase (NTRK) genes have rarely been reported in ganglioglioma. Similarly, echinoderm microtubule-associated protein-like (EML) 4 gene fusion has been described in lung cancer, but none has been reported in ganglioglioma. This report discusses the care of a 72-year-old man presenting with medication-refractory, left-sided focal seizures who was found to have a nongadolinium-enhancing, T2-hyperintense, right frontoparietal lesion. The patient received resection, and histological analysis found a World Health Organization grade I ganglioglioma, with genetic analysis demonstrating an EML4-NTRK3 gene fusion protein. To our knowledge, this is the first report of an NTRK3 fusion, EML4-NTRK3, in an adult ganglioglioma, which is otherwise mostly associated with BRAF alterations and activation of the mitogen-activated protein kinase signaling pathway. Further studies are needed to elucidate the function of the resultant fusion protein and determine whether it may serve as a future therapeutic target.
Sections du résumé
BACKGROUND
BACKGROUND
Gangliogliomas are well-differentiated, slow-growing glioneuronal neoplasms frequently reported to harbor upregulating alterations in the mitogen-activated protein kinase pathway, particularly serine-threonine protein kinase B-RAF alterations. Fusions involving neurotrophin tyrosine receptor kinase (NTRK) genes have rarely been reported in ganglioglioma. Similarly, echinoderm microtubule-associated protein-like (EML) 4 gene fusion has been described in lung cancer, but none has been reported in ganglioglioma.
OBSERVATIONS
METHODS
This report discusses the care of a 72-year-old man presenting with medication-refractory, left-sided focal seizures who was found to have a nongadolinium-enhancing, T2-hyperintense, right frontoparietal lesion. The patient received resection, and histological analysis found a World Health Organization grade I ganglioglioma, with genetic analysis demonstrating an EML4-NTRK3 gene fusion protein.
LESSONS
CONCLUSIONS
To our knowledge, this is the first report of an NTRK3 fusion, EML4-NTRK3, in an adult ganglioglioma, which is otherwise mostly associated with BRAF alterations and activation of the mitogen-activated protein kinase signaling pathway. Further studies are needed to elucidate the function of the resultant fusion protein and determine whether it may serve as a future therapeutic target.
Identifiants
pubmed: 36130567
doi: 10.3171/CASE21645
pii: CASE21645
pmc: PMC9379748
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2017 Sep 05;9(9):
pubmed: 28872581
J Biol Chem. 2002 Jan 11;277(2):1301-9
pubmed: 11694528
Pharmacol Res. 2013 Feb;68(1):68-94
pubmed: 23201355
Acta Neuropathol. 2018 Aug;136(2):239-253
pubmed: 29766299
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979374
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol Commun. 2018 Jun 7;6(1):47
pubmed: 29880043
Clin Lung Cancer. 2012 Jul;13(4):252-66
pubmed: 22154278
J Neuropathol Exp Neurol. 1947 Jan;6(1):24-34
pubmed: 20283034
Neuropathology. 2018 Mar 4;:
pubmed: 29502353
Transl Lung Cancer Res. 2012 Sep;1(3):179-93
pubmed: 25806180
Nat Biotechnol. 2015 Mar;33(3):306-12
pubmed: 25485619
Clin Pharmacol Ther. 2014 Jan;95(1):15-23
pubmed: 24091716
Brain Tumor Pathol. 2019 Jul;36(3):121-128
pubmed: 31011918
JCO Precis Oncol. 2021 Jan 14;1:
pubmed: 34036219
J Neurooncol. 2002 Sep;59(2):173-83
pubmed: 12241112
Neuromolecular Med. 2014 Sep;16(3):529-39
pubmed: 24840578
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Acta Neuropathol Commun. 2020 Jul 14;8(1):107
pubmed: 32665022
Pharmacol Ther. 2017 May;173:58-66
pubmed: 28174090
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii5-viii15
pubmed: 31738427